drugset / Trial / NCT06461299

Study to Evaluate the Efficacy, Safety, and Tolerability of Sarecycline for Treating Periorificial Dermatitis

NCT06461299

Phase 4 Completed 9 enrolled The Dermatology Institute of Boston
NaSingle-groupOpen-labelTreatment

Summary

A Single-Center Pilot Study to Evaluate the Efficacy, Safety, and Tolerability of Sarecycline for Treating Periorificial Dermatitis

Timeline

Start
2023-07-17
Primary completion
2024-03-31
Completion
2024-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Sarecycline Small molecule 60 mg Oral
Subject Sarecycline Small molecule 100 mg Oral
Subject Sarecycline Small molecule 150 mg Oral

Indications